Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.


Expert Highlights Evolution of Biosimilars in Oncology

June 29th 2018

Michael Savin, MD, discusses the emergence of biosimilars in oncology, and why there are still obstacles with incorporating them into clinical practice.

Dr. Novik on the Sustainability of Drug Development

June 29th 2018

Yelena Novik, MD, associate professor, New York University Langone’s Perlmutter Cancer Center, discusses the sustainability of drug development in oncology.

Dr. Kolberg Explains the Approval Process for Biosimilars

June 28th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, explains the approval process for biosimilars.

EU Prescribing Patterns for Rituximab Biosimilars in Non-Hodgkin Lymphoma

June 28th 2018

European patients with non-Hodgkin lymphoma are more likely to be prescribed a rituximab biosimilar if they are in better overall health, have indolent histology, and have follicular lymphoma.

Dr. Kwa on the Potential Impact of Biosimilars in Oncology

June 27th 2018

Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the potential impact of biosimilars in oncology.

Dr. Novik on the Adoption of Biosimilars in Breast Cancer

June 23rd 2018

Yelena Novik, MD, associate professor, Department of Medicine, New York University’s Perlmutter Cancer Center, discusses the adoption of biosimilars in breast cancer.

Dr. Kolberg Discusses the Central Pathology Review of ABP 980

June 21st 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses the central pathology review of the trastuzumab (Herceptin) biosimilar ABP 980.

FDA Strategizes to Step Up Introduction of Lower-Cost Drugs and NGS

June 19th 2018

The market for biosimilar introduction is “extremely unstable,” but the FDA is working to ease the launch of more affordable cancer medicines with a strategy that includes an attempt to reduce anticompetitive behavior.

Dr. Savin on the Evolution of Biosimilars

June 16th 2018

Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the evolution of biosimilars.

Dr. Mitri Discusses the Promise of Trastuzumab Biosimilars

June 12th 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the promise of trastuzumab (Herceptin) biosimilars.

Dr. Savin Discusses the Future of Biosimilars in Oncology

June 12th 2018

Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the future of biosimilars in oncology.

Dr. Kolberg Discusses the LILAC Study of ABP 980

June 9th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses the LILAC study of the biosimilar ABP 980.

Expert Predicts the Trajectory of Biosimilars in Oncology

June 8th 2018

Haythem Y. Ali, MD, discusses the state of biosimilar development and implementation in the field of oncology.

Trastuzumab Biosimilar Demonstrates Equivalence to Reference Product in HER2-Positive Breast Cancer

June 6th 2018

The pathologic complete response rate associated with the trastuzumab biosimilar ABP 980 was equivalent to that of reference trastuzumab based on central laboratory evaluation in patients with HER2-positive early breast cancer enrolled in the phase III LILAC study.

48 Week PFS Similar for MYL-1401O, Trastuzumab in HER2-Positive Metastatic Breast Cancer

June 5th 2018

MYL-1401O (Ogivri; trastuzumab-dkst) added to a taxane as initial therapy followed by MYL-1401O monotherapy as maintenance resulted in a nearly identical rate of progression-free survival compared with trastuzumab (Herceptin) in patients with HER2-positive metastatic breast cancer.

Bevacizumab Biosimilar Demonstrates Similar Response Rate, Survival as European Originator

June 5th 2018

The bevacizumab biosimilar PF-06439535 demonstrated similarity to the European Union bevacizumab reference product for overall response rate, with similar pharmacokinetic and immunogenicity profiles for patients with advanced non-squamous non-small cell lung cancer.

Dr. Verma Discusses Biosimilars for Trastuzumab

June 1st 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses the potential role for trastuzumab (Herceptin) biosimilars.

Dr. Denes on the Use of Biosimilars in Oncology

May 30th 2018

Alex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses the use of biosimilars in the treatment of patients with cancer.

Dr. Mitri on Impact of Trastuzumab Biosimilar FDA Approval

May 29th 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the impact of the FDA-approval of the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst).

Dr. Ali Explains Misconceptions About Biosimilars

May 25th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses misconceptions about biosimilars in oncology.

NEXT PAGE
PREVIOUS PAGE